A Phase 3 interventional study of Anlotinib and Placebos in Small Cell Lung Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Status unknown at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-29.
Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies testing anlotinib in Small Cell Lung Carcinoma — 15 open to participants now, 16 under way, 2 of them phase 3. anlotinib · Small Cell Lung Carcinoma.
Among the 35 studies testing anlotinib in Small Cell Lung Carcinoma, this one is the 3rd largest by planned enrollment, is one of 8 that started in 2019, is one of 4 in phase 3, and was the 10th registered.
1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.
Browse Small Cell Lung Carcinoma studies →15 of the 35 studies testing anlotinib in Small Cell Lung Carcinoma are open now, in 1 country. Recruiting first, the newest first:
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–75
Fudan University · Sites in China
Ages 18–75
Jinming Yu · Sites in China
Ages 18–75
Zhejiang Cancer Hospital · Sites in China
Ages 18–75
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Ages 18–85
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 25 · Phase 3 5 · Phase 4 3
First in 2017; this study’s year is marked. 8 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 184 is above the median of 56 across 1,077 interventional studies indexed under Small Cell Lung Carcinoma.
Median enrollment 40 across the 35 interventional studies. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 35 have an industry lead sponsor. The 10 most frequent:
This study is registered under Chia Tai Tianqing Pharmaceutical Group Co., Ltd., one of the names counted as Sino Biopharmaceutical Limited. Under that name alone:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.
Sino Biopharmaceutical Limited has 5 studies filed under Small Cell Lung Carcinoma — fewer than ten, so there is no comparison to draw.
8 of the studies testing anlotinib in Small Cell Lung Carcinoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07358676Tianjin Medical University Cancer Institute and HospitalA Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer | 2027-01-01 |
| NCT07388875China Medical University, ChinaSacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC | 2027-02-01 |
| NCT06931145Peking Union Medical College HospitalBenmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer | 2027-04-30 |
| NCT07022301First Affiliated Hospital of Wannan Medical CollegeSintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy | 2027-05 |
| NCT07501169Sichuan UniversitySacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | 2027-08-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 35 studies testing anlotinib in Small Cell Lung Carcinoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Anlotinib hydrochloride is a multi-targeted receptor tyrosine kinase inhibitor that targets angiogenesis-related kinases such as VEGFR1/2/3, FGFR1/2/3, and other tumor-associated kinases involved in cell proliferation such as PDGFRα/β, c-Kit, and Ret have significant inhibitory activities.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anlotinib hydrochloride capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) and topotecan 1.5mg/m2 IV d1-5.
Drug: Anlotinib · Drug: Topotecan
Anlotinib hydrochloride placebo given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) and topotecan 1.5mg/m2 IV d1-5.
Drug: Placebos · Drug: Topotecan
Progression Free Survival (PFS) evaluated by IRC
PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause; IRC defined as Independent Review Committee.
Time frame: up to 24 months
Progression Free Survival (PFS) evaluated by investigator
PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.
Time frame: up to 24 months
Overall survival (OS)
OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.
Time frame: up to 24 months
Overall Response Rate (ORR)
Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR).
Time frame: up to 24 months
Disease Control Rate (DCR)
Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD).
Time frame: up to 24 months
Duration of Overall Response (DOR)
The time when the patient first achieved complete or partial remission to disease progression.
Time frame: up to 24 months
PFS rate at month 6
The percentage of PFS at month 6.
Time frame: up to 6 months
OS rate at month 6
The percentage of OS at month 6.
Time frame: up to 6 months
OS rate at month 12
The percentage of OS at month 12.
Time frame: up to 12 months
The efficacy of intracranial lesions
To evaluate the efficacy of of intracranial lesions.
Time frame: up to 24 months
Adverse Event (AE)
Safety data
Time frame: up to 24 months
Serious Adverse Event (SAE)
Safety data
Time frame: up to 24 months
Abnormal laboratory test index
Safety data
Time frame: up to 24 months
Start is estimated for Oct 2019; primary completion for Jul 2021, 21 months later.
Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's planned 21 months is below that.
Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Anlotinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. →